PSP Research LLC reported 42 positions worth $14.41M for the quarter ended Sep 30, 2026, down 46.2% on the prior quarter. It opened 1 new position, added to 0, trimmed 26 and exited 31. Its largest holding is Sera Prognostics, Inc. at 34.8% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| SERA Sera Prognostics, Inc. | +2.40M | – | $5.01M | 34.76% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| IRON Disc Medicine, Inc. | -8,000 | -100.0% | $585.12K | Exited |
| RAPP Rapport Therapeutics, Inc. | -14.0K | -100.0% | $583.38K | Exited |
| RARE Ultragenyx Pharmaceutical Inc. | -17.0K | -100.0% | $567.63K | Exited |
| GLUE Monte Rosa Therapeutics, Inc. | -23.0K | -100.0% | $556.60K | Exited |
| IONS Ionis Pharmaceuticals Inc | -6,800 | -100.0% | $539.17K | Exited |
| PHVS Pharvaris N.V. | -15.0K | -100.0% | $518.70K | Exited |
| ACAD Acadia Pharmaceuticals Inc | -19.8K | -100.0% | $500.08K | Exited |
| PTCT Ptc Therapeutics, Inc. | -6,000 | -100.0% | $489.42K | Exited |
| CLDX Celldex Therapeutics, Inc. | -13.0K | -100.0% | $483.73K | Exited |
| COGT Cogent Biosciences, Inc. | -12.0K | -100.0% | $464.40K | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| SERA Sera Prognostics, Inc. | +2.40M | $5.01M | 34.76% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| IRON Disc Medicine, Inc. | -8,000 | $585.12K | 2.18% |
| RAPP Rapport Therapeutics, Inc. | -14.0K | $583.38K | 2.18% |
| RARE Ultragenyx Pharmaceutical Inc. | -17.0K | $567.63K | 2.12% |
| GLUE Monte Rosa Therapeutics, Inc. | -23.0K | $556.60K | 2.08% |
| IONS Ionis Pharmaceuticals Inc | -6,800 | $539.17K | 2.01% |
| PHVS Pharvaris N.V. | -15.0K | $518.70K | 1.94% |
| ACAD Acadia Pharmaceuticals Inc | -19.8K | $500.08K | 1.87% |
| PTCT Ptc Therapeutics, Inc. | -6,000 | $489.42K | 1.83% |
| CLDX Celldex Therapeutics, Inc. | -13.0K | $483.73K | 1.81% |
| COGT Cogent Biosciences, Inc. | -12.0K | $464.40K | 1.73% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | SERA Sera Prognostics, Inc. | Healthcare | 2.40M | $5.01M | 34.76% | +2.40M | – | New | 4.75% |
| 2 | HALO Halozyme Therapeutics, Inc. | Healthcare | 3,000 | $331.20K | 2.3% | -4,000 | -57.1% | Reduced | 0% |
| 3 | MDGL Madrigal Pharmaceuticals, Inc. | Healthcare | 600 | $302.38K | 2.1% | 0 | 0.0% | Unchanged | 0% |
| 4 | EXEL Exelixis, Inc. | Healthcare | 5,000 | $292.05K | 2.03% | -3,000 | -37.5% | Reduced | 0% |
| 5 | RPRX Royalty Pharma plc | Financial Services | 5,000 | $291.80K | 2.02% | -6,000 | -54.5% | Reduced | 0% |
| 6 | ARGX Argenx Se | Healthcare | 300 | $287.67K | 2% | -341 | -53.2% | Reduced | 0% |
| 7 | NRIX Nurix Therapeutics, Inc. | Healthcare | 12.0K | $284.52K | 1.97% | -13.0K | -52.0% | Reduced | 0.01% |
| 8 | TGTX Tg Therapeutics, Inc. | Healthcare | 5,000 | $278.90K | 1.94% | -5,000 | -50.0% | Reduced | 0% |
| 9 | TARS Tarsus Pharmaceuticals, Inc. | Healthcare | 3,500 | $275.14K | 1.91% | -3,500 | -50.0% | Reduced | 0.01% |
| 10 | HRMY Harmony Biosciences Holdings, Inc. | Healthcare | 7,000 | $274.82K | 1.91% | -3,000 | -30.0% | Reduced | 0.01% |
| 11 | ARQT Arcutis Biotherapeutics, Inc. | Healthcare | 10.0K | $264.30K | 1.83% | -9,700 | -49.2% | Reduced | 0.01% |
| 12 | KNSA Kiniksa Pharmaceuticals International, plc | Healthcare | 3,500 | $261.14K | 1.81% | -1,500 | -30.0% | Reduced | 0% |
| 13 | SUPN Supernus Pharmaceuticals, Inc. | Healthcare | 6,000 | $258.24K | 1.79% | 0 | 0.0% | Unchanged | 0.01% |
| 14 | IMNM Immunome Inc. | Healthcare | 12.0K | $258.12K | 1.79% | -6,000 | -33.3% | Reduced | 0.01% |
| 15 | NBIX Neurocrine Biosciences Inc | Healthcare | 1,800 | $255.31K | 1.77% | -1,200 | -40.0% | Reduced | 0% |
Tip. Select a row to see that position’s full history at PSP Research.
As of its Q3 2026 13F filing, PSP Research LLC’s five largest positions were Sera Prognostics, Inc. (SERA) at 34.8%, Halozyme Therapeutics, Inc. (HALO) at 2.3%, Madrigal Pharmaceuticals, Inc. (MDGL) at 2.1%, Exelixis, Inc. (EXEL) at 2.0%, Royalty Pharma plc (RPRX) at 2.0% of the reported portfolio.
PSP Research LLC reported a 13F portfolio worth $14.41M across 42 positions for Q3 2026. That is down 46.2% from the previous quarter.
Its largest purchases by value were Sera Prognostics, Inc. ($5.01M). It opened 1 new positions.
Its largest sales by value were Disc Medicine, Inc. ($585.12K), Rapport Therapeutics, Inc. ($583.38K), Ultragenyx Pharmaceutical Inc. ($567.63K). It exited 31 positions entirely.
From the Form 13F-HR reports PSP Research LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.